Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir

Clinical Infectious Diseases

Volumn 47, Issue 9, 2008, Pages 1222-1225

  Siccardi, Marco ^a,b   D'Avolio, Antonio ^a   Baietto, Lorena ^a   Gibbons, Sara ^b   Sciandra, Mauro ^a   Colucci, Daniela ^a   Bonora, Stefano ^a   Khoo, Saye ^b   Back, David J ^b   Di Perri, Giovanni ^a   Owen, Andrew ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; GENOMIC DNA; PREGNANE X RECEPTOR; TENOFOVIR;

ANTIVIRAL THERAPY; ARTICLE; DNA EXTRACTION; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; RECEPTORS, STEROID;

EID: 53349160769     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592304     Document Type: Article

References (20)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Departmetn of Health and Human Services. 29 January 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 19 September 2008.
2. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50:3801-8.
3. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-94.
4. Rodriguez Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42:291-5.
5. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21:41-6.
6. Owen A, Pirmohamed M, Khoo SH, Back DJ. Pharmacogenetics of HIV therapy. Pharmacogenet Genomics 2006; 16:693-703.
7. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102:1016-23.
8. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276:14581-7.
9. Martin P, Riley R, Back DJ, Owen A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Brit J Pharmacol 2008; 153:805-19.
10. Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001; 29:1454-9.
11. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36:169-81.
12. Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11:555-72.
13. Owen A. The impact of host pharmacogenetics on antiretroviral drug disposition. Curr Infect Dis Rep 2006; 8:401-8.
14. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61:914-8.
15. Ford J, Boffito M, Maitland D, et al. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother 2006; 58:1009-16.
16. Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir trough is associated with efficacy and safety: definition of therapeutic range [abstract 645. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
17. Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Technology Web page. Available at: http://www.kkgt.nl Accessed 19 September 2008.
18. Owen A, Chandler B, Back DJ, Khoo SH. Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antiviral Therapy 2004; 9:819-21.
19. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190-4.
20. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999; 57:1147-52.